Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
According to our market capitalization data, Eli Lilly (LLY) reached a market cap of $676.92 billion, securing the top spot among global Biotech companies. Novo Nordisk A/S (NOVO-B.CO) and Johnson & Johnson (JNJ) follow closely behind. The data was last updated on January 22, 2025.
| Rank | Name | Market Cap | Price | MCap(30D) | MCap(1Y) | Country |
|---|---|---|---|---|---|---|
|
1
|
 Eli Lilly
LLY
|
$676.92 B | $752.71 |
-6.7%
|
18.7%
|
United States
|
|
2
|
 Novo Nordisk A/S
NOVO-B.CO
|
$365.09 B | $82.22 |
-7.6%
|
-17.7%
|
Denmark
|
|
3
|
 Johnson & Johnson
JNJ
|
$347.78 B | $144.45 |
1.6%
|
-4.4%
|
United States
|
|
4
|
 Novo Nordisk
NVO
|
$335.53 B | $80.64 |
-7.3%
|
-22.3%
|
Denmark
|
|
5
|
 AbbVie
ABBV
|
$300.53 B | $170.07 |
-3.2%
|
6.8%
|
United States
|
|
6
|
 Roche
ROG.SW
|
$243.91 B | $303.35 |
8.2%
|
17.2%
|
Switzerland
|
|
7
|
 Merck
MRK
|
$242.59 B | $95.90 |
-3.2%
|
-17.5%
|
United States
|
|
8
|
 Thermo Fisher Scientific
TMO
|
$220.26 B | $575.85 |
8.3%
|
4.3%
|
United States
|
|
9
|
 AstraZeneca
AZN
|
$211.43 B | $68.18 |
-1.4%
|
0.05%
|
United Kingdom
|
|
10
|
 Novartis
NVS
|
$197.43 B | $98.75 |
1.4%
|
-3.9%
|
Switzerland
|
|
11
|
 Pfizer
PFE
|
$148.34 B | $26.18 |
-0.37%
|
-0.57%
|
United States
|
|
12
|
 Amgen
AMGN
|
$147.53 B | $274.46 |
3.9%
|
-8.6%
|
United States
|
|
13
|
 Sanofi
SNY
|
$128.55 B | $51.27 |
1.9%
|
2.9%
|
France
|
|
14
|
 Gilead Sciences
GILD
|
$116.07 B | $93.14 |
-1.1%
|
21.7%
|
United States
|
|
15
|
 Bristol-Myers Squibb
BMY
|
$115.86 B | $57.12 |
-0.16%
|
19.5%
|
United States
|
|
16
|
 Vertex Pharmaceuticals
VRTX
|
$110.70 B | $429.84 |
4.8%
|
-2.7%
|
United States
|
|
17
|
 CSL
CSL.AX
|
$82.06 B | $169.48 |
-4.3%
|
-6.0%
|
Australia
|
|
18
|
 Regeneron Pharmaceuticals
REGN
|
$75.23 B | $684.62 |
-3.7%
|
-27.9%
|
United States
|
|
19
|
 Zoetis
ZTS
|
$75.07 B | $166.39 |
1.7%
|
-10.3%
|
United States
|
|
20
|
 Chugai Pharmaceutical
4519.T
|
$69.96 B | $42.51 |
-4.4%
|
20.4%
|
Japan
|
|
21
|
 GlaxoSmithKline
GSK
|
$68.38 B | $33.51 |
-5.7%
|
-15.1%
|
United Kingdom
|
|
22
|
 Daiichi Sankyō
4568.T
|
$54.14 B | $28.78 |
-5.0%
|
-4.0%
|
Japan
|
|
23
|
 Samsung Biologics
207940.KS
|
$50.36 B | $707.51 |
8.2%
|
28.7%
|
South Korea
|
|
24
|
 Sun Pharmaceutical
SUNPHARMA.NS
|
$49.94 B | $20.81 |
-3.8%
|
29.3%
|
India
|
|
25
|
 Lonza
LONN.SW
|
$46.06 B | $638.71 |
7.7%
|
56.2%
|
Switzerland
|
|
26
|
 Agilent Technologies
A
|
$43.33 B | $151.72 |
12.3%
|
16.7%
|
United States
|
|
27
|
 Takeda Pharmaceutical
TAK
|
$41.01 B | $12.94 |
-0.99%
|
-11.5%
|
Japan
|
|
28
|
 Jiangsu Hengrui Medicine
600276.SS
|
$38.98 B | $6.11 |
-8.1%
|
6.2%
|
China
|
|
29
|
 Argenx
ARGX
|
$38.57 B | $640.44 |
2.8%
|
75.0%
|
Netherlands
|
|
30
|
 UCB
UCB.VI
|
$36.47 B | $192.11 |
-3.8%
|
120.6%
|
Belgium
|
|
31
|
 Alnylam Pharmaceuticals
ALNY
|
$34.39 B | $266.59 |
8.9%
|
39.7%
|
United States
|
|
32
|
 DexCom
DXCM
|
$34.07 B | $87.23 |
7.6%
|
-32.1%
|
United States
|
|
33
|
 BioNTech
BNTX
|
$27.66 B | $115.37 |
2.7%
|
16.9%
|
Germany
|
|
34
|
 Otsuka Holdings
4578.T
|
$27.63 B | $51.44 |
-5.0%
|
41.8%
|
Japan
|
|
35
|
 Celltrion
068270.KS
|
$27.10 B | $125.94 |
-0.62%
|
5.3%
|
South Korea
|
|
36
|
 Novozymes
NZYM.VI
|
$26.67 B | $57.48 |
-0.22%
|
23.2%
|
Denmark
|
|
37
|
 Novonesis A/S
NSIS-B.CO
|
$26.61 B | $57.31 |
-0.05%
|
16.1%
|
Denmark
|
|
38
|
 Teva Pharmaceutical Industries
TEVA
|
$24.69 B | $21.77 |
-2.7%
|
82.0%
|
Israel
|
|
39
|
 Illumina
ILMN
|
$22.95 B | $144.73 |
1.1%
|
-0.18%
|
United States
|
|
40
|
 Bayer
BAYN.DE
|
$21.48 B | $21.87 |
8.7%
|
-35.3%
|
Germany
|
|
41
|
 Biogen
BIIB
|
$20.75 B | $142.37 |
-5.4%
|
-44.0%
|
United States
|
|
42
|
 LabCorp
LH
|
$20.40 B | $243.94 |
4.0%
|
6.6%
|
United States
|
|
43
|
 BeiGene
BGNE
|
$20.21 B | $218.70 |
15.7%
|
29.5%
|
China
|
|
44
|
 Sandoz Group
SDZ.SW
|
$20.17 B | $45.95 |
12.5%
|
45.8%
|
Switzerland
|
|
45
|
 Divis Laboratories
DIVISLAB.NS
|
$17.85 B | $67.25 |
1.8%
|
65.4%
|
India
|
|
46
|
 Royalty Pharma
RPRX
|
$17.72 B | $30.07 |
19.0%
|
5.4%
|
United Kingdom
|
|
47
|
 Astellas Pharma
4503.T
|
$17.10 B | $9.55 |
1.3%
|
-5.6%
|
Japan
|
|
48
|
 ICON plc
ICLR
|
$16.89 B | $204.54 |
-3.8%
|
-22.3%
|
Ireland
|
|
49
|
 Summit Therapeutics
SMMT
|
$16.85 B | $22.85 |
-12.4%
|
307.1%
|
United Kingdom
|
|
50
|
 United Therapeutics
UTHR
|
$16.63 B | $372.50 |
-0.54%
|
64.8%
|
United States
|
|
51
|
 Baxter
BAX
|
$16.15 B | $31.63 |
6.5%
|
-17.0%
|
United States
|
|
52
|
 Moderna
MRNA
|
$15.09 B | $39.22 |
-10.9%
|
-64.8%
|
United States
|
|
53
|
 Revvity
RVTY
|
$15.05 B | $123.64 |
5.4%
|
10.4%
|
United States
|
|
54
|
 Neurocrine Biosciences
NBIX
|
$14.80 B | $146.21 |
4.9%
|
2.0%
|
United States
|
|
55
|
 Incyte
INCY
|
$13.92 B | $72.25 |
2.9%
|
16.3%
|
United States
|
|
56
|
 bioMérieux
BIM.PA
|
$13.81 B | $117.13 |
5.8%
|
6.5%
|
France
|
|
57
|
 Genmab A/S
GMAB.CO
|
$13.81 B | $217.36 |
3.4%
|
-18.0%
|
|
|
58
|
 Insmed
INSM
|
$13.80 B | $77.15 |
2.8%
|
156.8%
|
United States
|
|
59
|
 Intra-Cellular Therapies
ITCI
|
$13.53 B | $127.36 |
48.1%
|
89.9%
|
United States
|
|
60
|
 Cipla
CIPLA.NS
|
$13.45 B | $16.65 |
-2.9%
|
3.0%
|
India
|
|
61
|
 Genmab
GMAB
|
$13.41 B | $21.11 |
6.5%
|
-22.0%
|
Denmark
|
|
62
|
 Hansoh Pharma
3692.HK
|
$13.26 B | $2.23 |
-5.4%
|
40.3%
|
China
|
|
63
|
 Viatris
VTRS
|
$13.21 B | $11.07 |
-8.9%
|
-0.05%
|
United States
|
|
64
|
 Alteogen
196170.KQ
|
$12.68 B | $238.63 |
13.4%
|
371.7%
|
South Korea
|
|
65
|
 Dr. Reddy's
RDY
|
$12.60 B | $14.98 |
-2.6%
|
12.5%
|
India
|
|
66
|
 Bio-Techne
TECH
|
$12.44 B | $78.27 |
3.8%
|
5.1%
|
United States
|
|
67
|
 Torrent Pharmaceuticals
TORNTPHARM.NS
|
$12.40 B | $36.64 |
-4.9%
|
31.1%
|
India
|
|
68
|
 Shionogi
4507.T
|
$12.21 B | $14.35 |
2.5%
|
-3.1%
|
Japan
|
|
69
|
 Mankind Pharma
MANKIND.NS
|
$12.01 B | $29.12 |
-8.6%
|
29.4%
|
India
|
|
70
|
 Recordati
REC.MI
|
$11.98 B | $58.10 |
9.2%
|
14.6%
|
Italy
|
|
71
|
 BioMarin Pharmaceutical
BMRN
|
$11.90 B | $62.42 |
-7.7%
|
-33.9%
|
United States
|
|
72
|
 Catalent
CTLT
|
$11.52 B | $63.48 |
0.00%
|
29.0%
|
United States
|
|
73
|
 Zydus Lifesciences
ZYDUSLIFE.NS
|
$11.39 B | $11.32 |
4.4%
|
33.3%
|
India
|
|
74
|
 Lupin Limited
LUPIN.NS
|
$11.29 B | $24.75 |
-1.3%
|
49.3%
|
India
|
|
75
|
 Sarepta Therapeutics
SRPT
|
$11.18 B | $117.06 |
-3.2%
|
-2.6%
|
United States
|
|
76
|
 Vaxcyte
PCVX
|
$10.93 B | $87.68 |
-0.71%
|
31.0%
|
United States
|
|
77
|
 Medpace
MEDP
|
$10.79 B | $347.05 |
-1.6%
|
12.8%
|
United States
|
|
78
|
 Qiagen
QGEN
|
$10.61 B | $47.72 |
5.4%
|
10.2%
|
Netherlands
|
|
79
|
 Swedish Orphan Biovitrum
SOBI.ST
|
$10.58 B | $30.80 |
6.6%
|
18.8%
|
Sweden
|
|
80
|
 Ipsen
IPN.PA
|
$10.47 B | $123.18 |
9.0%
|
12.4%
|
France
|
|
81
|
 Exact Sciences
EXAS
|
$9.94 B | $53.72 |
-11.0%
|
-21.2%
|
United States
|
|
82
|
 Exelixis
EXEL
|
$9.81 B | $34.37 |
7.0%
|
60.1%
|
United States
|
|
83
|
 Repligen
RGEN
|
$9.51 B | $169.71 |
9.2%
|
-14.2%
|
United States
|
|
84
|
 WuXi Biologics
WXXWY
|
$9.46 B | $4.60 |
3.5%
|
-37.4%
|
China
|
|
85
|
 Glaukos
GKOS
|
$8.80 B | $159.59 |
3.4%
|
69.0%
|
United States
|
|
86
|
 Charles River Laboratories
CRL
|
$8.66 B | $169.43 |
-12.2%
|
-23.6%
|
United States
|
|
87
|
 Cerevel Therapeutics
CERE
|
$8.19 B | $44.96 |
0.00%
|
6.7%
|
United States
|
|
88
|
 Roivant Sciences
ROIV
|
$8.16 B | $11.21 |
-8.8%
|
4.7%
|
United Kingdom
|
|
89
|
 Eisai
4523.T
|
$8.01 B | $28.42 |
-0.35%
|
-37.6%
|
Japan
|
|
90
|
 Aurobindo Pharma
AUROPHARMA.NS
|
$8.01 B | $13.79 |
-6.5%
|
1.4%
|
India
|
|
91
|
 Tempus AI
TEM
|
$7.78 B | $49.40 |
1.0%
|
-12.7%
|
United States
|
|
92
|
 kyowa Kirin
4151.T
|
$7.70 B | $14.71 |
-0.39%
|
0.79%
|
Japan
|
|
93
|
 Revolution Medicines
RVMD
|
$7.64 B | $41.37 |
-9.2%
|
47.2%
|
United States
|
|
94
|
 Ascendis Pharma
ASND
|
$7.41 B | $123.84 |
-5.6%
|
-4.0%
|
Denmark
|
|
95
|
 Zealand Pharma
ZEAL.CO
|
$7.38 B | $104.46 |
0.75%
|
64.8%
|
Denmark
|
|
96
|
 Jazz Pharmaceuticals
JAZZ
|
$7.36 B | $121.71 |
-1.9%
|
1.1%
|
Ireland
|
|
97
|
 Orion Corporation
ORNAV.HE
|
$7.26 B | $51.27 |
15.5%
|
20.7%
|
Finland
|
|
98
|
 Akeso
9926.HK
|
$7.22 B | $8.04 |
-0.42%
|
37.7%
|
China
|
|
99
|
 Blueprint Medicines
BPMC
|
$7.14 B | $112.37 |
21.7%
|
32.4%
|
United States
|
|
100
|
 Alkem Laboratories
ALKEM.NS
|
$7.13 B | $59.60 |
-2.7%
|
6.1%
|
India
|
|
101
|
 Halozyme Therapeutics
HALO
|
$7.06 B | $55.52 |
15.3%
|
57.7%
|
United States
|
|
102
|
 Abbott India
ABBOTINDIA.NS
|
$6.83 B | $321.36 |
-1.3%
|
11.9%
|
India
|
|
103
|
 Madrigal Pharmaceuticals
MDGL
|
$6.80 B | $311.95 |
-5.9%
|
28.2%
|
United States
|
|
104
|
 BridgeBio Pharma
BBIO
|
$6.73 B | $35.60 |
18.4%
|
-9.0%
|
United States
|
|
105
|
 Legend Biotech
LEGN
|
$6.68 B | $36.42 |
-0.43%
|
-46.3%
|
United States
|
|
106
|
 Yuhan
000100.KS
|
$6.66 B | $90.29 |
12.2%
|
117.5%
|
South Korea
|
|
107
|
 Lantheus Holdings
LNTH
|
$6.45 B | $92.73 |
0.19%
|
74.3%
|
United States
|
|
108
|
 Corcept Therapeutics
CORT
|
$6.20 B | $59.01 |
6.0%
|
136.0%
|
United States
|
|
109
|
 Elanco
ELAN
|
$5.99 B | $12.12 |
1.2%
|
-18.3%
|
United States
|
|
110
|
 DiaSorin
DIA.MI
|
$5.87 B | $110.05 |
6.5%
|
26.2%
|
Italy
|
|
111
|
 Hikma Pharmaceuticals
HIK.L
|
$5.84 B | $2629.89 |
0.65%
|
6.6%
|
United Kingdom
|
|
112
|
 Grifols
GRFS
|
$5.77 B | $7.36 |
-6.0%
|
0.00%
|
Spain
|
|
113
|
 Nuvalent
NUVL
|
$5.68 B | $80.00 |
-8.2%
|
-1.4%
|
United States
|
|
114
|
 Telix Pharmaceuticals
TLX.AX
|
$5.63 B | $16.83 |
7.6%
|
143.6%
|
Australia
|
|
115
|
 Cytokinetics
CYTK
|
$5.50 B | $46.58 |
-5.7%
|
-46.1%
|
United States
|
|
116
|
 Lundbeck
HLUN-B.CO
|
$5.41 B | $5.66 |
-3.4%
|
17.6%
|
Denmark
|
|
117
|
 Biocon
BIOCON.NS
|
$5.38 B | $4.49 |
11.9%
|
46.8%
|
India
|
|
118
|
 H. Lundbeck A/S
HLUN-A.CO
|
$5.37 B | $4.58 |
-2.7%
|
12.3%
|
Denmark
|
|
119
|
 Ionis Pharmaceuticals
IONS
|
$5.15 B | $32.59 |
-14.0%
|
-39.3%
|
United States
|
|
120
|
 Richter Gedeon
RIG2.F
|
$4.94 B | $27.09 |
-0.39%
|
0.00%
|
|
|
121
|
 Bachem
BANB.SW
|
$4.93 B | $65.79 |
2.6%
|
6.5%
|
Switzerland
|
|
122
|
 Glenmark Pharmaceuticals
GLENMARK.NS
|
$4.90 B | $17.37 |
-1.7%
|
70.5%
|
India
|
|
123
|
 Alkermes
ALKS
|
$4.88 B | $30.16 |
1.5%
|
5.5%
|
Ireland
|
|
124
|
 Axsome Therapeutics
AXSM
|
$4.84 B | $99.91 |
5.7%
|
2.7%
|
United States
|
|
125
|
 Siegfried Holding
SFZN.SW
|
$4.84 B | $1114.93 |
3.3%
|
19.3%
|
Switzerland
|
|
126
|
 Ono Pharmaceutical
4528.T
|
$4.83 B | $10.29 |
3.3%
|
-35.4%
|
Japan
|
|
127
|
 ALK-Abelló
ALK-B.CO
|
$4.76 B | $21.52 |
-3.7%
|
43.6%
|
Denmark
|
|
128
|
 Ipca Laboratories
IPCALAB.NS
|
$4.58 B | $18.04 |
-0.39%
|
45.0%
|
India
|
|
129
|
 TG Therapeutics
TGTX
|
$4.51 B | $29.00 |
-8.1%
|
86.9%
|
United States
|
|
130
|
 Verona Pharma
VRNA
|
$4.39 B | $53.59 |
7.5%
|
184.3%
|
United Kingdom
|
|
131
|
 Krystal Biotech
KRYS
|
$4.35 B | $151.29 |
-6.4%
|
13.8%
|
United States
|
|
132
|
 Galenica
GALE.SW
|
$4.35 B | $87.21 |
6.2%
|
8.5%
|
Switzerland
|
|
133
|
 Scholar Rock Holding
SRRK
|
$4.29 B | $45.78 |
-5.3%
|
192.8%
|
United States
|
|
134
|
 Organon
OGN
|
$4.08 B | $15.83 |
6.9%
|
2.8%
|
United States
|
|
135
|
 China Resources Pharmaceutical Group
3320.HK
|
$4.08 B | $0.65 |
-10.8%
|
10.8%
|
Hong Kong
|
|
136
|
 Alvotech
ALVO
|
$4.01 B | $13.28 |
6.4%
|
-6.2%
|
Iceland
|
|
137
|
 Hualan Biological Engineering
002007.SZ
|
$3.99 B | $2.18 |
-11.1%
|
-13.3%
|
China
|
|
138
|
 Rohto Pharmaceutical
4527.T
|
$3.99 B | $17.47 |
-5.6%
|
-9.3%
|
Japan
|
|
139
|
 Immunovant
IMVT
|
$3.98 B | $23.50 |
-8.5%
|
-39.4%
|
United States
|
|
140
|
 Biohaven Pharmaceutical
BHVN
|
$3.96 B | $39.15 |
5.1%
|
-22.2%
|
United States
|
|
141
|
 Ultragenyx
RARE
|
$3.89 B | $42.17 |
-8.6%
|
-10.1%
|
United States
|
|
142
|
 Amneal Pharmaceuticals
AMRX
|
$3.89 B | $8.42 |
5.2%
|
50.7%
|
United States
|
|
143
|
 Viking Therapeutics
VKTX
|
$3.79 B | $34.06 |
-22.9%
|
40.3%
|
United States
|
|
144
|
 ADMA Biologics
ADMA
|
$3.78 B | $16.01 |
-8.0%
|
204.0%
|
United States
|
|
145
|
 Apellis Pharmaceuticals
APLS
|
$3.78 B | $30.35 |
-10.2%
|
-54.8%
|
United States
|
|
146
|
 Piramal Pharma
PPLPHARMA.NS
|
$3.70 B | $2.80 |
-8.7%
|
63.6%
|
India
|
|
147
|
 Crinetics Pharmaceuticals
CRNX
|
$3.59 B | $38.73 |
-30.8%
|
-0.69%
|
United States
|
|
148
|
 CRISPR Therapeutics
CRSP
|
$3.57 B | $41.88 |
1.4%
|
-37.3%
|
Switzerland
|
|
149
|
 Laurus Labs
LAURUSLABS.NS
|
$3.56 B | $6.60 |
-0.46%
|
41.9%
|
India
|
|
150
|
 Avidity Biosciences
RNA
|
$3.56 B | $29.85 |
-7.8%
|
186.1%
|
United States
|
|
151
|
 Arcellx
ACLX
|
$3.55 B | $65.57 |
-14.3%
|
18.5%
|
United States
|
|
152
|
 Sinopharm
1099.HK
|
$3.50 B | $2.61 |
-6.6%
|
11.9%
|
China
|
|
153
|
 Rhythm Pharmaceuticals
RYTM
|
$3.48 B | $56.65 |
-2.3%
|
29.7%
|
United States
|
|
154
|
 Santen Pharmaceutical
4536.T
|
$3.41 B | $10.00 |
-0.32%
|
6.3%
|
Japan
|
|
155
|
 PTC Therapeutics
PTCT
|
$3.41 B | $44.16 |
-3.3%
|
56.8%
|
United States
|
|
156
|
 Perrigo
PRGO
|
$3.30 B | $24.18 |
-4.6%
|
-24.3%
|
Ireland
|
|
157
|
 Laboratorios Farmaceuticos Rovi
ROVI.MC
|
$3.28 B | $64.19 |
0.73%
|
-1.2%
|
Spain
|
|
158
|
 Tecan
TECN.SW
|
$3.25 B | $253.01 |
11.9%
|
-29.3%
|
Switzerland
|
|
159
|
 Olink Holding
OLK
|
$3.24 B | $26.08 |
0.00%
|
4.0%
|
Sweden
|
|
160
|
 Twist Bioscience
TWST
|
$3.15 B | $52.80 |
-2.7%
|
38.3%
|
United States
|
|
161
|
 Gland Pharma
GLAND.NS
|
$3.11 B | $18.90 |
-8.5%
|
-12.9%
|
India
|
|
162
|
 Jamjoom Pharmaceuticals Factory Company
4015.SR
|
$3.09 B | $44.20 |
8.0%
|
22.0%
|
Saudi Arabia
|
|
163
|
 ACADIA Pharmaceuticals
ACAD
|
$2.97 B | $17.87 |
2.9%
|
-37.6%
|
United States
|
|
164
|
 Vericel
VCEL
|
$2.96 B | $60.06 |
3.1%
|
39.8%
|
United States
|
|
165
|
 Xenon Pharmaceuticals
XENE
|
$2.96 B | $38.88 |
1.5%
|
-13.5%
|
Canada
|
|
166
|
 Zai Lab
ZLAB
|
$2.96 B | $26.05 |
-3.1%
|
13.2%
|
China
|
|
167
|
 Recursion Pharmaceuticals
RXRX
|
$2.90 B | $7.40 |
-9.8%
|
-38.6%
|
United States
|
|
168
|
 Novocure
NVCR
|
$2.89 B | $26.70 |
-12.9%
|
90.4%
|
|
|
169
|
 Morphic Therapeutic
MORF
|
$2.86 B | $56.99 |
0.00%
|
104.7%
|
United States
|
|
170
|
 Morphosys
MOR
|
$2.86 B | $18.96 |
0.00%
|
107.9%
|
Germany
|
|
171
|
 Amicus Therapeutics
FOLD
|
$2.84 B | $9.51 |
-3.9%
|
-24.5%
|
United States
|
|
172
|
 MoonLake Immunotherapeutics
MLTX
|
$2.83 B | $44.95 |
-13.0%
|
-18.9%
|
Switzerland
|
|
173
|
 Genscript Biotech
1548.HK
|
$2.82 B | $1.32 |
-5.1%
|
-42.2%
|
China
|
|
174
|
 Kymera Therapeutics
KYMR
|
$2.81 B | $43.36 |
-0.51%
|
29.9%
|
United States
|
|
175
|
 Bausch Health
BHC
|
$2.81 B | $7.61 |
-0.80%
|
-8.9%
|
Canada
|
|
176
|
 WuXi AppTec
2359.HK
|
$2.74 B | $7.07 |
-3.7%
|
-32.2%
|
China
|
|
177
|
 Catalyst Pharmaceuticals
CPRX
|
$2.73 B | $22.86 |
5.4%
|
52.6%
|
United States
|
|
178
|
 KOBAYASHI Pharmaceutical
4967.T
|
$2.71 B | $36.48 |
-2.6%
|
-12.2%
|
Japan
|
|
179
|
 Merus
MRUS
|
$2.71 B | $39.53 |
-6.3%
|
14.8%
|
Netherlands
|
|
180
|
 Virbac SA
VIRP.PA
|
$2.71 B | $323.05 |
2.6%
|
-5.3%
|
France
|
|
181
|
 Natco Pharma
NATCOPHARM.NS
|
$2.62 B | $14.61 |
-7.8%
|
46.9%
|
India
|
|
182
|
 SpringWorks Therapeutics
SWTX
|
$2.57 B | $34.61 |
-5.9%
|
-17.1%
|
United States
|
|
183
|
 NewAmsterdam Pharma Company
NAMS
|
$2.50 B | $23.39 |
-8.7%
|
6.7%
|
Netherlands
|
|
184
|
 Azenta
AZTA
|
$2.48 B | $54.17 |
4.7%
|
-20.9%
|
United States
|
|
185
|
 Arrowhead Pharmaceuticals
ARWR
|
$2.44 B | $19.59 |
-0.36%
|
-43.0%
|
United States
|
|
186
|
 HUTCHMED
HCM
|
$2.43 B | $14.22 |
-0.63%
|
2.5%
|
Hong Kong
|
|
187
|
 Longboard Pharmaceuticals
LBPH
|
$2.34 B | $59.98 |
0.00%
|
130.2%
|
United States
|
|
188
|
 Janux Therapeutics
JANX
|
$2.33 B | $39.76 |
-27.5%
|
325.1%
|
United States
|
|
189
|
 Alembic Pharmaceuticals
APLLTD.NS
|
$2.32 B | $11.79 |
-2.5%
|
4.0%
|
India
|
|
190
|
 BB Biotech
BION.SW
|
$2.30 B | $41.95 |
7.2%
|
-10.2%
|
Switzerland
|
|
191
|
 ImmunityBio
IBRX
|
$2.28 B | $3.12 |
11.8%
|
-12.5%
|
United States
|
|
192
|
 Mirum Pharmaceuticals
MIRM
|
$2.28 B | $47.53 |
11.3%
|
77.2%
|
United States
|
|
193
|
 CG Oncology
CGON
|
$2.25 B | $29.62 |
2.8%
|
-21.8%
|
United States
|
|
194
|
 Protagonist Therapeutics
PTGX
|
$2.25 B | $37.68 |
-6.3%
|
47.4%
|
United States
|
|
195
|
 Harmony Biosciences
HRMY
|
$2.24 B | $39.33 |
14.7%
|
23.1%
|
United States
|
|
196
|
 Apogee Therapeutics
APGE
|
$2.22 B | $38.96 |
-21.7%
|
6.6%
|
United States
|
|
197
|
 Bavarian Nordic
BAVA.CO
|
$2.20 B | $28.08 |
3.4%
|
25.8%
|
Denmark
|
|
198
|
 Centessa Pharmaceuticals
CNTA
|
$2.17 B | $16.47 |
-4.7%
|
100.2%
|
United Kingdom
|
|
199
|
 GeneDx Holdings
WGS
|
$2.17 B | $78.99 |
-10.2%
|
1868.3%
|
United States
|
|
200
|
 Certara
CERT
|
$2.16 B | $13.40 |
9.0%
|
-28.9%
|
United States
|